Welcome to our dedicated page for Aclaris Therapeutics news (Ticker: ACRS), a resource for investors and traders seeking the latest updates and insights on Aclaris Therapeutics stock.
Aclaris Therapeutics, Inc. (NASDAQ: ACRS) is a clinical-stage biopharmaceutical company developing novel product candidates for immuno-inflammatory diseases. The ACRS news page on Stock Titan aggregates company announcements, clinical data readouts, financial updates, and investor events drawn from press releases and regulatory disclosures.
Recent Aclaris news has focused on its immunology pipeline, including ATI-2138, a potent and selective oral ITK/JAK3 inhibitor, and its antibody franchise targeting TSLP and IL-4/IL-13 pathways. The company has reported positive Phase 2a results for ATI-2138 in moderate-to-severe atopic dermatitis, initiation and progress of a Phase 2 trial of its anti-TSLP monoclonal antibody bosakitug (ATI-045) in atopic dermatitis, and Phase 1a and Phase 1b development of its bispecific anti-TSLP/IL-4Rα antibody ATI-052, including a Phase 1b proof-of-concept trial in atopic dermatitis.
Investors and followers of ACRS can use this news feed to track key milestones such as interim and top line clinical results, updates on additional indications for ATI-2138, and timelines for proof-of-concept and later-stage trials. The page also captures corporate developments, including quarterly and year-to-date financial results, cash runway commentary, index inclusions such as the Nasdaq Biotechnology Index, and participation in healthcare and biotechnology conferences and R&D Day events.
By reviewing the ACRS news page regularly, readers can follow how Aclaris communicates progress across its oral kinase inhibitor and biologics franchises, how it describes the evolution of its multi-stage portfolio, and how financial and strategic updates align with its stated focus on patients with immuno-inflammatory diseases who lack satisfactory treatment options.
Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a biopharmaceutical company, will participate in a fireside chat during the Virtual SVB Securities Global Biopharma Conference on February 14, 2023, at 9:20 AM ET. The event can be accessed via a webcast on the company’s website, where it will be archived for 30 days. Aclaris focuses on developing innovative drug candidates for immuno-inflammatory diseases, aiming to meet the needs of patients with limited treatment options. The company features a strong R&D pipeline exploring protein kinase regulation.
Aclaris Therapeutics, Inc. (NASDAQ: ACRS) provided a positive corporate outlook for 2023, highlighting key clinical milestones for their lead programs, zunsemetinib and ATI-1777. The company plans to release topline data for several trials, including rheumatoid arthritis and atopic dermatitis, in mid to late 2023. Aclaris is also progressing ATI-2138 for T cell-mediated diseases and ATI-2231 for oncology. An upcoming presentation at the J.P. Morgan Healthcare Conference on January 11 will further discuss the company’s developments. Aclaris aims to address unmet needs in immuno-inflammatory diseases.
Aclaris Therapeutics (NASDAQ: ACRS) and Pediatrix Therapeutics have announced a license agreement allowing Pediatrix to develop, manufacture, and commercialize ATI-1777, a soft Janus kinase (JAK) 1/3 inhibitor, for atopic dermatitis in Greater China. Aclaris will receive a $5 million upfront payment and could earn up to $91 million in milestone payments, alongside tiered royalties on net sales. This partnership aims to address the unmet medical needs for patients in the region, enhancing the global potential of Aclaris’ drug development efforts.
Aclaris Therapeutics has announced significant leadership changes effective January 1, 2023. Dr. Neal Walker will transition to Chair of the Board, while Dr. Douglas Manion is appointed CEO, succeeding Walker. Kevin Balthaser takes over as CFO following Frank Ruffo's retirement, and Matthew Rothman is appointed General Counsel. These transitions reflect Aclaris' strategic evolution in developing novel drug candidates for immuno-inflammatory diseases, emphasizing a leadership team with substantial pharmaceutical experience.
Aclaris Therapeutics, Inc. (NASDAQ: ACRS) announced participation in two healthcare investor conferences in November 2022. On November 16, at 5:00 PM GMT/12:00 PM EST, Dr. Neal Walker, CEO, will engage in a fireside chat at the Jefferies London Healthcare Conference.
Additionally, on November 29 at 9:30 AM EST, he will participate in another fireside chat at the 34th Annual Piper Sandler Healthcare Conference in New York. Webcasts for both events will be available on Aclaris' website and archived for 30 days.
Aclaris Therapeutics (NASDAQ: ACRS) announced significant developments in its drug pipeline, completing enrollment in the Phase 2a trial of zunsemetinib for hidradenitis suppurativa, with topline data expected in mid-2023. Additionally, the company reported a patent license agreement with Lilly, generating $17.6 million in revenue. Financially, Aclaris reported a net loss of $20.0 million for Q3 2022, an improvement from $21.1 million in Q3 2021, yet R&D expenses rose to $23.7 million due to ongoing clinical trials. The company’s cash reserves stand at $248.1 million, projected to fund operations through 2025.
Aclaris Therapeutics, Inc. (NASDAQ: ACRS) announced the appointment of Robert A. Doody Jr. as Vice President of Investor Relations on September 27, 2022. CEO Neal Walker expressed enthusiasm about strengthening the team with experienced industry veterans. Doody brings nearly 20 years of experience in biotechnology and has previously held investor relations positions at Provention Bio, Idera Pharmaceuticals, and ViroPharma. His expertise is expected to enhance Aclaris' engagement with investors as the company develops novel drug candidates for immuno-inflammatory diseases.
Aclaris Therapeutics, Inc. (NASDAQ: ACRS) announced that Dr. Neal Walker, CEO, will present a company overview at the H.C. Wainwright 24th Annual Global Investment Conference. The virtual presentation will be accessible on-demand starting September 12, 2022, at 7:00 a.m. ET. Management will be available for virtual 1x1 meetings throughout the day. A webcast of the presentation will be available on Aclaris' website for at least 30 days. Aclaris focuses on developing innovative drug candidates for patients with immuno-inflammatory diseases.
Aclaris Therapeutics (NASDAQ: ACRS) announced a non-exclusive patent license agreement with Eli Lilly for the use of baricitinib, a JAK inhibitor, to treat alopecia areata. The deal includes an upfront payment, regulatory and commercial milestones, and royalties. Jim Loerop, Chief Business Officer, emphasized the significance of the patent portfolio for commercialization, highlighting Aclaris' investment in its JAK inhibitor patents. Financial terms remain undisclosed, but the partnership positions Aclaris favorably within the competitive landscape of immuno-inflammatory disease treatments.
Aclaris Therapeutics (NASDAQ: ACRS) announced key updates on August 3, 2022, including the appointment of Douglas Manion, M.D., as President and COO. The company initiated Phase 2a study activities for Psoriatic Arthritis and reported a net loss of $20.5 million for Q2 2022, an increase from $18.2 million in Q2 2021. Total revenue for the quarter was $1.5 million, down from $1.8 million year-over-year. R&D expenses surged to $18.8 million, driven by advancements in clinical trials. Aclaris's cash position is robust, with $256 million available, ensuring operations through 2025.
FAQ
What is the current stock price of Aclaris Therapeutics (ACRS)?
What is the market cap of Aclaris Therapeutics (ACRS)?
